M Juliana McElrath1. 1. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Abstract
PURPOSE OF REVIEW: The development and availability of new-generation adjuvants beyond aluminum and emulsion formulations, together with a deeper understanding of the mechanistic role of adjuvant formulations in stimulating innate immunity and offer opportunities to improve candidate vaccine designs intended to protect against HIV-1 acquisition. RECENT FINDINGS: Currently, major efforts in vaccine development focus on improving prime-boost vaccine regimens to enhance efficacy beyond 31% observed in the RV144 phase 3 study and to develop a pathway to induce broadly reactive HIV neutralizing antibodies. Advances in HIV-1 envelope (Env) immunogen design and improved adjuvant formulations are moving at a parallel pace. This review highlights steps underway to rationally pair vaccine concepts with improved adjuvant formulations in preclinical and early phase 1 clinical evaluation. SUMMARY: New adjuvants with immune-potentiating properties are currently being tested in combination with recent HIV Env-containing immunogens in prime-boost and subunit protein-only regimens. Greater emphasis is being applied to formulation science, delivery, and targeted safety and immune evaluation with these adjuvants in clinical trials. The need to develop an HIV vaccine that induces more potent and long-lived protective immunity will necessitate continued efforts to optimize adjuvanted vaccine formulations.
PURPOSE OF REVIEW: The development and availability of new-generation adjuvants beyond aluminum and emulsion formulations, together with a deeper understanding of the mechanistic role of adjuvant formulations in stimulating innate immunity and offer opportunities to improve candidate vaccine designs intended to protect against HIV-1 acquisition. RECENT FINDINGS: Currently, major efforts in vaccine development focus on improving prime-boost vaccine regimens to enhance efficacy beyond 31% observed in the RV144 phase 3 study and to develop a pathway to induce broadly reactive HIV neutralizing antibodies. Advances in HIV-1envelope (Env) immunogen design and improved adjuvant formulations are moving at a parallel pace. This review highlights steps underway to rationally pair vaccine concepts with improved adjuvant formulations in preclinical and early phase 1 clinical evaluation. SUMMARY: New adjuvants with immune-potentiating properties are currently being tested in combination with recent HIV Env-containing immunogens in prime-boost and subunit protein-only regimens. Greater emphasis is being applied to formulation science, delivery, and targeted safety and immune evaluation with these adjuvants in clinical trials. The need to develop an HIV vaccine that induces more potent and long-lived protective immunity will necessitate continued efforts to optimize adjuvanted vaccine formulations.
Authors: Paul A Goepfert; Georgia D Tomaras; Helen Horton; David Montefiori; Guido Ferrari; Mark Deers; Gerald Voss; Marguerite Koutsoukos; Louise Pedneault; Pierre Vandepapeliere; M Juliana McElrath; Paul Spearman; Jonathan D Fuchs; Beryl A Koblin; William A Blattner; Sharon Frey; Lindsey R Baden; Clayton Harro; Thomas Evans Journal: Vaccine Date: 2006-08-10 Impact factor: 3.641
Authors: Cornelia Gujer; Christopher Sundling; Robert A Seder; Gunilla B Karlsson Hedestam; Karin Loré Journal: Immunology Date: 2011-11 Impact factor: 7.397
Authors: Amy W Chung; Manu P Kumar; Kelly B Arnold; Wen Han Yu; Matthew K Schoen; Laura J Dunphy; Todd J Suscovich; Nicole Frahm; Caitlyn Linde; Alison E Mahan; Michelle Hoffner; Hendrik Streeck; Margaret E Ackerman; M Juliana McElrath; Hanneke Schuitemaker; Maria G Pau; Lindsey R Baden; Jerome H Kim; Nelson L Michael; Dan H Barouch; Douglas A Lauffenburger; Galit Alter Journal: Cell Date: 2015-11-05 Impact factor: 41.582
Authors: Amy W Chung; Musie Ghebremichael; Hannah Robinson; Eric Brown; Ickwon Choi; Sophie Lane; Anne-Sophie Dugast; Matthew K Schoen; Morgane Rolland; Todd J Suscovich; Alison E Mahan; Larry Liao; Hendrik Streeck; Charla Andrews; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Mark S de Souza; Jaranit Kaewkungwal; Punnee Pitisuttithum; Donald Francis; Nelson L Michael; Jerome H Kim; Chris Bailey-Kellogg; Margaret E Ackerman; Galit Alter Journal: Sci Transl Med Date: 2014-03-19 Impact factor: 17.956
Authors: Nicole L Yates; Hua-Xin Liao; Youyi Fong; Allan deCamp; Nathan A Vandergrift; William T Williams; S Munir Alam; Guido Ferrari; Zhi-yong Yang; Kelly E Seaton; Phillip W Berman; Michael D Alpert; David T Evans; Robert J O'Connell; Donald Francis; Faruk Sinangil; Carter Lee; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Abraham Pinter; Susan Zolla-Pazner; Peter B Gilbert; Gary J Nabel; Nelson L Michael; Jerome H Kim; David C Montefiori; Barton F Haynes; Georgia D Tomaras Journal: Sci Transl Med Date: 2014-03-19 Impact factor: 17.956
Authors: Hui Li; Shuyi Wang; Rui Kong; Wenge Ding; Fang-Hua Lee; Zahra Parker; Eunlim Kim; Gerald H Learn; Paul Hahn; Ben Policicchio; Egidio Brocca-Cofano; Claire Deleage; Xingpei Hao; Gwo-Yu Chuang; Jason Gorman; Matthew Gardner; Mark G Lewis; Theodora Hatziioannou; Sampa Santra; Cristian Apetrei; Ivona Pandrea; S Munir Alam; Hua-Xin Liao; Xiaoying Shen; Georgia D Tomaras; Michael Farzan; Elena Chertova; Brandon F Keele; Jacob D Estes; Jeffrey D Lifson; Robert W Doms; David C Montefiori; Barton F Haynes; Joseph G Sodroski; Peter D Kwong; Beatrice H Hahn; George M Shaw Journal: Proc Natl Acad Sci U S A Date: 2016-05-31 Impact factor: 12.779
Authors: Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore Journal: PLoS Pathog Date: 2013-09-19 Impact factor: 6.823
Authors: P J Klasse; Celia C LaBranche; Thomas J Ketas; Gabriel Ozorowski; Albert Cupo; Pavel Pugach; Rajesh P Ringe; Michael Golabek; Marit J van Gils; Miklos Guttman; Kelly K Lee; Ian A Wilson; Salvatore T Butera; Andrew B Ward; David C Montefiori; Rogier W Sanders; John P Moore Journal: PLoS Pathog Date: 2016-09-14 Impact factor: 6.823
Authors: Eliza D Hompe; Jesse F Mangold; Amit Kumar; Joshua A Eudailey; Erin McGuire; Barton F Haynes; M Anthony Moody; Peter F Wright; Genevieve G Fouda; Elena E Giorgi; Feng Gao; Sallie R Permar Journal: mSphere Date: 2020-06-03 Impact factor: 4.389
Authors: Joseph G Skeate; Wouter H Segerink; Mauricio D Garcia; Daniel J Fernandez; Ruben Prins; Kim P Lühen; Féline O Voss; Diane M Da Silva; W Martin Kast Journal: Front Immunol Date: 2020-09-25 Impact factor: 7.561